Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Health-related quality of life in patients with Waldenström macroglobulinemia: results from the ASPEN trial.

Future oncology (London, England) - 1 Jan 2024

Tedeschi Alessandra, Tam Constantine S, Owen Roger G, Buske Christian, Leblond Véronique, Dimopoulos Meletios, Garcia-Sanz Ramón, Castillo Jorge J, Trotman Judith, Treon Steven P, Yang Keri, Tang Boxiong, Allewelt Heather, Patel Sheel, Chan Wai Y, Cohen Aileen, Chen Shengnan, Barnes Gisoo

Abstract excerpt

Aim ASPEN is a randomized, open-label, Phase III study comparing zanubrutinib and ibrutinib in patients with Waldenström macroglobulinemia (WM).Materials & methods: Patient-reported outcomes were exploratory end points assessed using the EORTC QLQ-C30 and EQ-5D-5L VAS scores.Results: Overall, 201 patients (102 zanubrutinib; 99 ibrutinib) were enrolled. Clinically meaningful differences were observed in diarrhea...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenine
Share to Myeloid Differentiation Factor 88

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Patient Reported Outcome Measures

Share to Piperidines

Share to Pyrazoles

Share to Pyrimidines

Share to Quality of Life

Share to Waldenstrom Macroglobulinemia

Source

Open in PubMed Open full text

Identifiers

PMID: 39072392
DOI: 10.1080/14796694.2024.2355079
PMCID: PMC11485878

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Health-related quality of life in patients with Waldenström macroglobulinemia: results from the ASPEN trial.PMID 39072392Read ↗

[Clinical characteristics and prognosis of patients with Waldenström macroglobulinemia and its comparison with the Pivotal study].Semantic proximity Read ↗

Health-Related Quality of Life in 91 Patients with X-Linked Agammaglobulinemia.Semantic proximity Read ↗

First- versus second-generation Bruton tyrosine kinase inhibitors in Waldenström's Macroglobulinemia: A systematic review and meta-analysis.Semantic proximity Read ↗

A head-to-head Phase III study comparing zanubrutinib versus ibrutinib in patients with Waldenström macroglobulinemia.Semantic proximity Read ↗

Patient reported quality of life and medication adherence in Fabry disease patients treated with migalastat: A prospective, multicenter study.Semantic proximity Read ↗

Phase 1 study of ibrutinib and the CXCR4 antagonist ulocuplumab in CXCR4-mutated Waldenström macroglobulinemia.Semantic proximity Read ↗

A multicenter, open-label, phase II study of tirabrutinib (ONO/GS-4059) in patients with Waldenström's macroglobulinemia.Semantic proximity Read ↗

Evaluation of Symptom and Side Effect Bother in Cutaneous T-cell Lymphoma Patients Treated with Mogamulizumab or VorinostatSemantic proximity Read ↗

Migalastat improves diarrhea in patients with Fabry disease: clinical-biomarker correlations from the phase 3 FACETS trial.Semantic proximity Read ↗

Ibrutinib Plus Rituximab Versus Placebo Plus Rituximab for Waldenström's Macroglobulinemia: Final Analysis From the Randomized Phase III iNNOVATE Study.Semantic proximity Read ↗

Imiglucerase (Cerezyme) improves quality of life in patients with skeletal manifestations of Gaucher disease.Semantic proximity Read ↗

Dose reductions in patients with Waldenström macroglobulinaemia treated with ibrutinib.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.